Baltimore's school board joined districts across the country in suing drug makers over the skyrocketing costs of diabetes medications. The Baltimore City Board of School Commissioners want drug makers ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Sinclair joins VCCP from Grey Health and Wellness, where she served as president for just over four years. Creative agency ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Greenland is not green. It’s white. See the map, above, for visual proof. Most of the world’s habitable land is green, or ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

A new study by Mass General Brigham investigators shows persistent racial disparities and growing sex disparities between patients who discussed and received weight loss surgery between 2000 and 2020.